Related references
Note: Only part of the references are listed.The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History
Ronghua Gao et al.
MEDICAL SCIENCE MONITOR (2018)
Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome
Simon Correa et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention
Fardin Mirbolouk et al.
JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH (2018)
Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome
Jinjin Zhang et al.
BMC CARDIOVASCULAR DISORDERS (2017)
Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention
Liang Tang et al.
HEART AND VESSELS (2016)
Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction
Jawad Mazhar et al.
IJC HEART & VASCULATURE (2016)
Neutrophil/Lymphocyte Ratio as a Predictor of In-Hospital Major Adverse Cardiac Events, New-Onset Atrial Fibrillation, and No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction
Sherif Wagdy et al.
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY (2016)
Diabetes mellitus and female gender are the strongest predictors of poor collateral vessel development in patients with severe coronary artery stenosis
Ertan Yetkin et al.
ANGIOGENESIS (2015)
Comparison of Heritability of Cystatin C- and Creatinine-Based Estimates of Kidney Function and Their Relation to Heritability of Cardiovascular Disease
Johannes Arpegard et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Mild to Moderate Renal Impairment Is Associated With No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
Alparslan Kurtul et al.
ANGIOLOGY (2015)
The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality
Eun Ho Choo et al.
CORONARY ARTERY DISEASE (2014)
Transient no reflow following primary percutaneous coronary intervention
Hiroyuki Jinnouchi et al.
HEART AND VESSELS (2014)
Incidence and Outcomes of No-Reflow Phenomenon During Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction
Robert W. Harrison et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study
Rainer P. Woitas et al.
ATHEROSCLEROSIS (2013)
Myocardial 'no-reflow' - Diagnosis, pathophysiology and treatment
Dennis T. L. Wong et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Cystatin C as Prognostic Biomarker in ST-Segment Elevation Acute Myocardial Infarction
Doroteia Silva et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Coronary no reflow
Bryan G. Schwartz et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus
Peter Kubisz et al.
ACTA DIABETOLOGICA (2010)
Predictors and Long-term Prognosis of Angiographic Slow/No-Reflow Phenomenon During Emergency Percutaneous Coronary Intervention for ST-Elevated Acute Myocardial Infarction
Li Dong-bao et al.
CLINICAL CARDIOLOGY (2010)
5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
Gjin Ndrepepa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study
Till Keller et al.
EUROPEAN HEART JOURNAL (2009)
Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese
Li Ni et al.
STROKE (2007)
Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality
David Brosh et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
GFR estimation using cystatin C is not independent of body composition
Jamie Macdonald et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Cystatin C and the risk of death and cardiovascular events among elderly persons
MG Shlipak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement
EL Knight et al.
KIDNEY INTERNATIONAL (2004)
Coronary and myocardial angiography -: Angiographic assessment of both epicardial and myocardial perfusion
CM Gibson et al.
CIRCULATION (2004)
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials
EC Keeley et al.
LANCET (2003)
Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque
D Bonderman et al.
BLOOD (2002)
The coronary no-reflow phenomenon: a review of mechanisms and therapies
E Eeckhout et al.
EUROPEAN HEART JOURNAL (2001)
Share Paper
